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Abstract
Background: Anti-Aβ immunotherapy in transgenic mice reduces both diffuse and compact
amyloid deposits, improves memory function and clears early-stage phospho-tau aggregates. As
most Alzheimer disease cases occur well past midlife, the current study examined adoptive transfer
of anti-Aβ antibodies to 19- and 23-month old APP-transgenic mice.
Methods: We investigated the effects of weekly anti-Aβ antibody treatment on radial-arm water-
maze performance, parenchymal and vascular amyloid loads, and the presence of microhemorrhage
in the brain. 19-month-old mice were treated for 1, 2 or 3 months while 23-month-old mice were
treated for 5 months. Only the 23-month-old mice were subject to radial-arm water-maze testing.
Results: After 3 months of weekly injections, this passive immunization protocol completely
reversed learning and memory deficits in these mice, a benefit that was undiminished after 5
months of treatment. Dramatic reductions of diffuse Aβ immunostaining and parenchymal
Congophilic amyloid deposits were observed after five months, indicating that even well-
established amyloid deposits are susceptible to immunotherapy. However, cerebral amyloid
angiopathy increased substantially with immunotherapy, and some deposits were associated with
microhemorrhage. Reanalysis of results collected from an earlier time-course study demonstrated
that these increases in vascular deposits were dependent on the duration of immunotherapy.
Conclusions: The cognitive benefits of passive immunotherapy persist in spite of the presence of
vascular amyloid and small hemorrhages. These data suggest that clinical trials evaluating such
treatments will require precautions to minimize potential adverse events associated with
microhemorrhage.
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Background
Alzheimer's disease is characterized not only by the pres-
ence of parenchymal amyloid deposits and intracellular
tangles but also by the presence of amyloid deposits in the
vasculature, a condition referred to as cerebral amyloid
angiopathy (CAA). The CAA observed in both Alzheimer's
disease patients [1] and some of the transgenic mouse
models [2] is primarily composed of the shorter form of
amyloid beta (Aβ), Aβ1–40, while the majority of amyloid
deposits in the parenchyma are composed of Aβ1–42,
although the compact amyloid deposits also contain Aβ1–
40.
Anti-Aβ immunotherapy has been considered as a poten-
tial treatment for Alzheimer's disease for some time [3,4].
Active immunization with a vaccine including Aβ1–42
fibrils progressed to human clinical trials where its admin-
istration was suspended due to meningoencephalitits in a
subset of patients [5]. To date there have been pathology
reports on two patients who participated in the trial and
subsequently died [6,7]. Both reports note that while the
numbers of parenchymal amyloid deposits appeared
lower than expected in these cases, the CAA in these
patients did not appear outside the normal range for
Alzheimer's disease. In addition, one report mentioned
multiple cortical hemorrhages and the presence of hemo-
siderin around the CAA vessels [7].
Given the adverse reactions to the active immunization,
the irreversibility of such procedures and the variable anti-
body response to vaccines in older individuals [8], passive
immunization against the Aβ peptide emerged as an alter-
native immunotherapeutic strategy. Studies in young and
middle aged APP-transgenic mice have reported signifi-
cant amyloid reductions with passive immunization [9-
11]. Such treatments also demonstrate rapid improve-
ments of memory function in APP-transgenic mice, some-
times without detectable reductions in amyloid [12-14].
Most recently, intracranial administration of anti-Aβ anti-
bodies has been shown to not only remove Aβ but also
clear, early-stage, hyperphosphorylated-tau aggregates
[15]. Importantly, in the only prior study evaluating
adoptive antibody transfer in older APP-transgenic mice,
Pfeifer et al. [16] reported a doubling of cerebral microhe-
morrhages associated with significant reductions in amy-
loid burden after administration of an N-terminal specific
anti-Aβ antibody.
Materials and Methods
Experiment design
Mice derived from APP Tg2576 mice were obtained from
our breeding program at University of South Florida
started in 1996 [17]. For the 5-month treatment study, 13
APP-transgenic mice, aged 23 months, were assigned to
one of two groups. The first group received weekly intra-
peritoneal anti-Aβ antibody injections (antibody 2286;
mouse-monoclonal anti-human Aβ28–40 IgG1; Rinat Neu-
rosciences, Palo Alto, CA) for a period of 5 months (n =
6). The second group received weekly intraperitoneal anti-
AMN antibody (2906; mouse-monoclonal anti-Drosophila
amnesiac protein IgG1; Rinat Neurosciences, Palo Alto,
CA) injections for a period of 5 months (n = 7). Seven
nontransgenic mice were also assigned to one of two
groups. The first group received weekly intraperitoneal
anti-Aβ antibody injections for a period of 5 months (n =
4). The second group received weekly intraperitoneal anti-
AMN antibody injections for a period of 5 months (n = 3).
For the time course study of 1-, 2- or 3-month treatment,
22 APP-transgenic mice aged 19 months were assigned to
one of four experimental groups, as described previously
[14]. The first three groups received weekly intraperitoneal
anti-Aβ antibody injections for 3 months, 2 months or 1
month, ending when all mice were 22 months of age. The
fourth group received weekly intraperitoneal anti-AMN
antibody injections for 3 months.
Behavioral analysis
Following 3 and 5 months of treatment, the mice from the
5-month study were subjected to a two-day radial-arm
water-maze paradigm. The apparatus was a 6-arm maze as
described previously [18]. On day one, 15 trials were run
in three blocks of 5. A cohort of 4 mice were run sequen-
tially for each block (i.e., each of 4 mice get trial one, then
the same mice get trial two, etc.). After each 5-trial block,
a second cohort of mice was run permitting an extended
rest period before mice were exposed to the second block
of 5 trials. The goal arm was different for each mouse in a
cohort to minimize odor cues. The start arm was varied for
each trial, with the goal arm remaining constant for a
given individual for both days. For the first 11 trials, the
platform was alternately visible then hidden (hidden for
the last 4 trials). On day two, the mice were run in exactly
the same manner as day one except that the platform was
hidden forall trials. The number of errors (incorrect arm
entries) was measured in a one-minute time frame. As
standard practice, mice failing to make an arm choice in
20 seconds are assigned one error, but no mice in this
study had to be assigned an error in this manner. The
same individual administered the antibody treatments
and placed mice in the radial-arm water maze. Due to the
numbers of mice in the study the researcher was unaware
of treatment group identity of each mouse. Also, the
dependent measures in the radial-arm water-maze task are
quantitative, not evaluative, so the potential for tester bias
is reduced. In order to minimize the influence of individ-
ual trial variability, each mouse's errors for 3 consecutive
trials were averaged producing 5 data points for each day,
which were analyzed statistically by ANOVA using
StatView (SAS Institute Inc., NC).Journal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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Tissue preparation and histology
On the day of sacrifice mice were weighed, overdosed with
100 mg/kg Nembutal (Abbott laboratories, North Chi-
cago, IL), and then intracardially perfused with 25 mL of
0.9% sodium chloride. Brains were rapidly removed, and
the left half of the brain was immersion fixed for 24 h in
freshly prepared 4% paraformaldehyde in 100 mM KPO4
(pH 7.2) for histopathology. The hemi-brains were then
incubated for 24 h in 10%, 20% and 30% sucrose sequen-
tially for cyroprotection. Horizontal sections of 25 µ
thickness were collected using a sliding microtome and
stored at 4°C in Dulbecco's phosphate-buffered saline
with sodium azide (pH 7.2) to prevent microbial growth.
A series of 8 equally spaced tissue sections 600 µ apart
were randomly selected spanning the entire brain and
stained using free-floating immunohistochemistry for
total Aβ (rabbit polyclonal anti-pan Aβ; Biosource,
Camarillo, CA, 1:10,000) as previously described [2,14].
A second series of tissue sections 600 µm apart were
stained using 0.2% Congo red in NaCl-saturated 80% eth-
anol. Another set of sections were also mounted and
stained for hemosiderin using 2% potassium ferrocyanide
in 2% hydrochloric acid for 15 min, followed by a coun-
terstain in a 1% neutral red solution for 10 min. Quanti-
fication of Congo red staining and Aβ
immunohistochemistry was performed using the Image-
Pro Plus (Media Cybernetics, Silver Spring, MD) to ana-
lyze the percent area occupied by positive stain. One
region of the frontal cortex and three regions of the hip-
pocampus were analyzed (to ensure that there was no
regional bias in the hippocampal values). The initial anal-
ysis of Congo red was performed to give a total value. A
second analysis was performed after manually editing out
all of the parenchymal amyloid deposits to yield a percent
area restricted to vascular Congo red staining. To estimate
the parenchymal area of Congo red, we subtracted the vas-
cular amyloid values from the total percentage. For the
hemosiderin stain the numbers of Prussian blue-positive
sites were counted on all sections and the average number
of sites per section calculated. Looking at the sections at a
low magnification we were able to observe a qualitative
differences between animals; however, the percent area
was so low that many fields contained no positive stain.
Eight equally spaced sections were examined and the
number of positive profiles was determined and averaged
to a per-section value. To assess possible treatment-related
differences, the values for each treatment group were ana-
lyzed by one-way ANOVA followed by Fisher's LSD means
comparisons.
Results
Reversal of cognitive deficits by passive amyloid 
immunotherapy
The radial-arm water-maze task detects spatial learning
and memory deficits in transgenic mouse models [18,19].
We treated 23-month-old mice for 5 months with anti-Aβ
antibody 2286 or control antibody 2906 (against a Dro-
sophila-specific protein) and tested them for spatial navi-
gation learning in a two-day version of the radial-arm
water maze after 3 months of treatment and, using a new
platform location, again after 5 months of treatment. At
both testing times we found that APP-transgenic mice
treated with the control antibody failed to learn platform
location over two days of testing and were significantly
impaired compared to the nontransgenic mice treated
with either antibody (Fig. 1). However, APP-transgenic
mice administered the anti-Aβ antibodies demonstrated a
complete reversal of the impairment observed in the con-
trol-treated APP-transgenic mice, ending day two with a
mean performance near 0.5 errors per trial (Fig. 1).
Although learning at the later time point, when the mice
were 28 months of age, may have been slightly slower for
all groups, there was no impairment of the anti-Aβ anti-
body-treated APP.
Passive amyloid immunotherapy clears parenchymal Aβ 
deposits, but increases vascular amyloid
In a prior experiment examining the effects of passive anti-
Aβ immunotherapy for 1, 2 or 3 months in APP-trans-
genic mice killed at 21 months of age [14], we found a
time-dependent reduction of both Aβ immunostaining of
diffuse and fibrillar deposits and Congo-red staining of
fibrillar amyloid deposits. In the current study we found a
similar reduction in both Aβ immunostaining (Table 1)
and total Congo-red staining (Fig. 2A, left panel; p < 0.001
frontal cortex and p < 0.01 hippocampus) after 5 months
of immunotherapy. We noted that the bulk of what
remained was vascular amyloid. We then separately ana-
lyzed vascular and parenchymal deposits which revealed
a near 90% reduction in parenchymal deposits (p < 0.001)
but a 3–4 fold elevation of vascular Congo-red staining (p
< 0.0001; Fig. 2A, center and right panels, respectively).
We also separately analyzed vascular and parenchymal
Congo-red staining on mice from our earlier study [14],
treated passively for 1, 2 or 3 months with anti-Aβ or con-
trol antibody, and found a similar result. There was a
graded reduction in overall Congo-red staining nearing
75% as duration of antibody exposure increased (as
reported previously; Fig. 2B). However, when separated
into vascular Congo-red deposits and parenchymal
deposits, there was an antibody-exposure-time-dependent
increase in vascular deposition in both hippocampus and
frontal cortex (Fig. 2C; p < 0.05 frontal cortex and hippoc-
ampus) and a corresponding nearly 90% decrease in
parenchymal deposits (Fig. 2D; p < 0.001 in frontal cortex
and hippocampus).
These differences were readily observed examining micro-
graphs of sections from these mice. Mice treated with con-
trol antibodies revealed occasional cortical vascularJournal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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Spatial learning deficits in APP-transgenic mice were reversed following 3 and 5 months of immunization Figure 1
Spatial learning deficits in APP-transgenic mice were reversed following 3 and 5 months of immunization. Mice were tested in a 
two-day version of the radial-arm water maze. Solid lines represent APP-transgenic mice while dashed lines represent non-
transgenic mice. Open symbols indicate anti-AMN, control-antibody treatment (❍ : APP-transgenic, control antibody; : non-
transgenic, control antibody) while closed symbols indicate anti-Aβ antibody treatment (● : APP-transgenic, Aβ antibody; ▲ : 
nontransgenic, Aβ antibody). Panel A shows mean number of errors made over the two-day trial period following 3 months of 
immunization. Each data point is the average of 3 trials. Panel B shows the mean number of errors made over the 2-day trial 
period following 5 months of immunization. For both graphs * indicates p < 0.05, ** indicates p < 0.001 when the APP-trans-
genic mice receiving control antibody are compared with the remaining groups.Journal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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amyloid deposits (22 months, Fig. 3A, 28 months, Fig.
3C), while mice administered anti-Aβ antibodies had
increased amounts of vascular amyloid staining (3-month
treatment, Fig 3B; 5-month treatment, Fig 3D). Those ves-
sels containing amyloid following treatment with anti-Aβ
antibody also exhibited apparent increases in microglial
activation as measured by CD45 expression (Fig. 3F) com-
pared to mice treated with control antibody (Fig. 3E).
Unfortunately, the shifting numbers and sizes of vascular
and parenchymal deposits caused by the antibody therapy
greatly complicated measurement of microglial activation
per vascular deposit area so that this apparent increase in
staining intensity could not be quantified accurately.
Passive amyloid immunotherapy causes increased 
microhemorrhage
We used the Prussian blue histological stain to label
hemosiderin, a ferric oxide material produced in the
breakdown of hemoglobin. Extravenous blood in the
brain leads to microglial phagocytosis of the erythrocytes
and breakdown of the hemoglobin within them. These
ferric oxide-containing microglia are thus markers of past
hemorrhage. In untreated, aged APP-transgenic mice we
observed very few profiles positive for Prussian-blue stain-
ing in the frontal cortex (section counterstained with neu-
tral red; Fig. 4A). However, following anti-Aβ antibody
treatment for 5 months we observed an increase in the
number of Prussian-blue profiles in the frontal cortex,
which were readily detectable at a low magnification in
the microscope (Fig. 4B). In the absence of anti-Aβ treat-
ment, or even when treated with antibody for one month,
most vessels did not stain with Prussian blue, and could
be identified only using the red counterstain (Fig. 4C).
However, even with 3 months of anti-Aβ antibody treat-
ment we observed frequent vessels with associated Prus-
sian-blue staining (Fig 4D). Using adjacent sections
stained for Congo red, we confirmed that all vessels show-
ing microhemorrhage contained amyloid (Figs. 4E and
4F; we were unable to double-label Prussian blue-stained
sections with either Congo red or thioflavine-S). How-
ever, only a minority of vessels containing amyloid dem-
onstrated hemorrhage.
When we counted the number of Prussian blue-positive
profiles in those animals receiving control antibody there
was an average of one profile per every two sections (Fig.
5) and this number remained the same in both control
groups (aged 22 or 28 months). Following treatment with
anti-Aβ antibody for a period of two months we observed
a striking increase in Prussian-blue staining, approxi-
mately five times that observed in either the control group
or the mice immunized for one month (Fig. 5, p < 0.001).
Following this initial increase in Prussian-blue staining,
we observed a linear increase in staining associated with
increasing duration of anti-Aβ antibody treatment (Fig 5).
Five months of anti-Aβ antibody treatment demonstrated
a six-fold increase in Prussian-blue staining when com-
pared the control groups (Fig. 5).
Discussion
Earlier studies with vaccines against the Aβ peptide dem-
onstrated protection from the learning and memory defi-
cits associated with amyloid accumulation in APP-
transgenic mice [14,19]. Passive immunization protocols
with anti-Aβ antibodies also produced cognitive benefits,
in some cases even in the absence of significant reduction
in amyloid burden [12,13]. Our recent work found that 3
months of anti-Aβ treatment of 18-month-old APP-trans-
genic mice improved spontaneous alternation perform-
ance on the Y-maze [14]. In the present work we
confirmed that passive anti-amyloid immunotherapy can
reverse spatial learning deficits in APP-transgenic mice
and that this benefit of immunotherapy is retained, even
in aged mice (26 and 28 months old at testing) with long-
established amyloid pathology.
Additionally, we describe a more rapid means of testing
spatial reference memory to reveal learning and memory
deficits in APP-transgenic mice. This two-day version of
the radial arm water maze included greater spacing of
individual trials (mice spent time in their home cage after
every trial), combined with less spacing of aggregate trials
(fifteen trials per day rather than four or five) to facilitate
learning of platform location in the nontransgenic mice,
with a clear absence of learning in the age-matched trans-
genic mice.
A substantial reduction in total Congophilic amyloid
deposits was observed in old APP-transgenic mice treated
with anti-Aβ antibodies for 2 or more months. This
Table 1: Total Aβ load is significantly reduced following 5 months of anti-Aβ antibody treatment. Percent area occupied by positive 
immunohistochemical stain for Aβ is shown ± standard error of the mean for both the frontal cortex and hippocampus. Also shown is 
the percent reduction of Aβ observed following anti-Aβ antibody treatment
Region % area positive for Aβ: control 
treated
% area positive for Aβ: anti-Aβ 
treated
% reduction following anti-Aβ 
antibody treatment
Frontal Cortex 34.855 ± 2.265 9.681 ± 0.754 72
Hippocampus 23.994 ± 0.985 8.212 ± 0.596 66Journal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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Passive immunization with anti-Aβ antibodies decreases total and parenchymal amyloid loads while increasing vascular amyloid  in frontal cortex and hippocampus of APP-transgenic mice Figure 2
Passive immunization with anti-Aβ antibodies decreases total and parenchymal amyloid loads while increasing vascular amyloid 
in frontal cortex and hippocampus of APP-transgenic mice. Panel A shows total amyloid load measured with Congo red, vascu-
lar amyloid load and parenchymal amyloid load from APP-transgenic mice administered control IgG (C) or anti-Aβ IgG (Aβ) for 
a period of 5 months. Panels B-D show total amyloid load (Panel B), vascular amyloid load (Panel C) and parenchymal amyloid 
load (Panel D) from APP-transgenic mice administered control IgG for 3 months (Cont IgG) or anti-Aβ IgG for a period of 1, 
2, or 3 months (Anti-Aβ IgG). For all panels, the solid bar and solid line represent values from the frontal cortex, while the 
open bar and dashed line represent values from the hippocampus. ** p < 0.01.Journal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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Increased Congo red staining of blood vessels following anti-Aβ antibody administration is associated with activated microglia Figure 3
Increased Congo red staining of blood vessels following anti-Aβ antibody administration is associated with activated microglia. 
Panels A and B are from the frontal cortex of 22-month-old APP-transgenic mice immunized for 3 months with either control 
antibody (3A) or anti-Aβ antibody (3B). Panels C and D are from the frontal cortex of 28-month-old APP-transgenic mice 
immunized for 5 months with either control antibody (3C) or anti-Aβ antibody (3D). Panels E and F show a high-magnification 
image of CD45 immunohistochemistry (black) counterstained with Congo red (red) from 28-month-old APP-transgenic mice 
immunized for 5 months with either control antibody (Panel E) or anti-Aβ antibody (Panel F). Panels A-D, magnification = 
100X. Scale bar in Panel B = 50 µ for panels A-D. Panels E-F, magnification = 200X. Scale bar in Panel E = 25 µm for panels E-F.Journal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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Microhemorrhage associated with CAA following systemic administration of anti-Aβ antibodies Figure 4
Microhemorrhage associated with CAA following systemic administration of anti-Aβ antibodies. Panels A and B are low magni-
fication images of the frontal cortex of APP-transgenic mice receiving either control antibodies (Panel A) or anti-Aβ antibodies 
(Panel B) for a period of 5 months. Panels C and D show representative images of amyloid containing vessels stained for Prus-
sian blue (blue), counterstained with neutral red (red), from APP-transgenic mice receiving either control antibodies (Panel C) 
or anti-Aβ antibodies (Panel D) for a period of 3 months. Panel E shows a blood vessel in the frontal cortex stained for Prus-
sian blue (blue), counterstained with neutral red, from an APP transgenic mouse administered anti-Aβ antibodies for 5 months. 
Panel F shows the same blood vessel on an adjacent section stained for Congo red, indicating that the blood vessel does in fact 
contain amyloid. Scale bar panel A = 120 µm for panels A-B. Scale bar panel C = 25 µm for panels C-D. Scale bar in panel F = 
25 µm for panels E-F.Journal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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measurement of total Congo-red staining included both
parenchymal and vascular amyloid staining. When we
analyzed the sections for only vascular amyloid (CAA) we
found that this measure was significantly increased fol-
lowing 2, 3 and 5 months of anti-Aβ antibody treatment.
The remaining parenchymal amyloid load was almost
completely eliminated with this antibody approach.
Clearly, because total amyloid load was significantly
reduced not all amyloid was shifted into the vessels; but,
it appears that at least some of the Congophilic material
was redistributed to the vasculature. At the present time
the mechanism for this redistribution is unclear. How-
ever, one possibility is that the microglia associated with
the antibody-opsonized amyloid, either by phagocytosis
or surface binding, and transported the material to the
vasculature, possibly in an attempt to expel it. We and
others have shown evidence for microglial involvement in
the removal of amyloid using both intracranial anti-Aβ
antibody injections [11,21] and systemically adminis-
tered anti-Aβ antibody treatment [14], as well as ex vivo
studies [10,22]. Here we also report our impression that
microglia surrounding CAA vessels in immunized mice
expressed more CD45 than control transgenic mice. This
increased expression could be due to either increased
expression in the same number of microglial cells or an
increased number of microglial cells in these animals. It is
feasible that this microglial activation was simply in reac-
tion to the presence of increased amyloid in the blood ves-
sels. However, it is equally likely that microglia activated
by the opsonized material migrated to the vessels for dis-
posal of the amyloid.
Cerebral amyloid angiopathy (CAA) is defined as the dep-
osition of congophilic material in meningeal and cerebral
arteries and arterioles (capillaries and veins can also show
CAA but less frequently), and it occurs to some extent in
Number of Prussian blue-positive profiles increases with duration of anti-Aβ antibody exposure Figure 5
Number of Prussian blue-positive profiles increases with duration of anti-Aβ antibody exposure. The graph shows quantifica-
tion of the average number of Prussian blue-positive profiles per section from mice administered control IgG for 3 or 5 months 
(Cont) or anti-Aβ IgG for 1, 2, 3 or 5 months (anti-Aβ). ** p < 0.01.Journal of Neuroinflammation 2004, 1:24 http://www.jneuroinflammation.com/content/1/1/24
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nearly all Alzheimer's disease patients [23]. Severe CAA,
affecting about 15% of cases, can be associated with both
infarction and hemorrhagic injury [24,25]. It has also
been shown that the severity of CAA can be directly linked
to the severity of dementia in Alzheimer's disease patients
[26].
In the current study we found a significantly increased
number of microhemorrhages in the brain as detected by
Prussian-blue staining, associated with the increase in
CAA following passive immunization. Another transgenic
mouse model of amyloid deposition, the APP23 mice,
have been shown to deposit amyloid in both brain paren-
chyma and blood vessels and show a CAA associated
increase in spontaneous cerebral hemorrhages [27]. More-
over, Pfeifer et al. [16] showed that these spontaneous
hemorrhages were significantly increased following 5
months of passive immunization of 21-month-old APP23
mice using an anti-Aβ antibody with an N-terminal
epitope, similar to those typically developed in active
immunization with vaccines [4,28,29]. When young mice
(6 months of age) were immunized following the same
protocol, no hemorrhages were observed. More recently,
DeMattos et al. [30] showed that passive immunization
with an N-terminal antibody (3D6: directed against
amino acids 1–5 of Aβ) of PDAPP transgenic mice also
resulted in significantly increased microhemorrhage. They
were unable to detect increased microhemorrhage with a
mid-domain antibody (266: directed against amino acids
13–28 of Aβ). Notably, antibody 266 fails to bind Aβ
deposited in CAA vessels or amyloid plaques [31]. Impor-
tantly, Ferrer et al. [7] noted the presence of CAA and
microhemorrhage in the brain of one patient that partici-
pated in the Aβ-vaccine trial, even though the parenchy-
mal amyloid appeared lower than expected. Also, Nicoll et
al. [6] noted that CAA appeared unaffected in the brain of
another patient that participated in the Aβ-vaccine trial.
It remains to be determined whether these observations
regarding increased CAA and microhemorrhage in
transgenic mice are relevant to trials of passive immuno-
therapy in humans. It should be noted that, in spite of
extending the period of immunotherapy to 5 months,
there was no discernable loss of the cognitive benefits of
immunotherapy in the transgenic mice, all of whom
showed increased microhemorrhage. While the observa-
tion that antibody 266 does not result in vascular leakage
encourages testing of this idiotype, data from the Zurich
cohort of the Aβ vaccine trial argue that brain-reactive
antibodies may be important for cognitive benefits [32].
Conclusions
Our opinion is that these results suggest that passive
immunotherapy against Aβ should proceed with appro-
priate precautions taken to minimize the risk of hemor-
rhage (e.g., by excluding patients taking anticoagulants)
and instituting measures to detect such hemorrhages if
they do occur, irrespective of the antibody specificity or
proclivity for microhemorrhage in aged APP-transgenic
mice.
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